Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $299
AbbVie, Inc. -0.05%
AbbVie, Inc. ABBV | 208.42 | -0.05% |
Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:
ABBV) with a Overweight and raises the price target from $289 to $299.
